AI assistant
IMUGENE LIMITED — Capital/Financing Update 2022
Oct 18, 2022
65124_rns_2022-10-18_ab10aef2-e62f-466a-a915-aa5abd1beece.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [177 x 31] intentionally omitted <==
ASX Announcement
Letter to IMUOC Optionholders
Sydney, Australia, 19 October 2022 : Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company advises that the attached notice of expiry of IMUOC options letter was sent to all holders of IMUOC listed options (Options) which are exercisable at $0.054 each on or before 5:00 pm AEDT on Wednesday, 30 November 2022 (Expiry Date).
Official quotation of the Options will cease at close of trading on 24 November 2022, being four business days before the Expiry Date.
Holders of the Options can exercise all or part of their Options prior to the Expiry Date. Please find attached the sample “notice of exercise of options” for further instructions.
-End-
For more information please contact:
Leslie Chong
Managing Director and Chief Executive Officer
Investor Enquiries
Media Enquiries
Matt Wright
Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
View us on YouTube @Imugene Limited
IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM [email protected]
==> picture [42 x 42] intentionally omitted <==
About Imugene (ASX: IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immunooncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
Release authorised by the Managing Director and Chief Executive Officer Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia
IMUGENE LIMITED ACN 009 179 551
2
Imugene Limited Suite 12.01, Level 12 ABN 99 009 179 551 4-6 Bligh Street www.imugene.com Sydney NSW 2000 AUSTRALIA
==> picture [126 x 50] intentionally omitted <==
19 October 2022
Dear Option Holder,
RE: Notice of Expiry of IMUOC Options
We want to thank you for your continued support.
The 30 November 2022 expiry date for IMUOC listed options is approaching and the Company would like to remind option holders that the IMUOC options NOT exercised by 30 November 2022 will automatically lapse.
Please find below information required to be provided to you in accordance with the ASX Listing Rules.
| Listing Rules. | |
|---|---|
| Number of shares to be issued on exercise of options |
One fully paid ordinary share (ASX: IMU) per option that is exercised |
| Exerciseprice | $0.054per option |
| Due date forpayment | 30 November 2022 |
| Consequence of non-payment | Options will lapse |
| Datequotation of IMUOC on ASX will end | 24 November 2022(at end of trade) |
| Latest marketprice for IMU | $0.18(18 October 2022) |
| 3 Month IMU lowprice | $0.17(17 October 2022) |
| 3 Month IMU highprice | $0.30(10 August 2022) |
| Underwriting | The IMUOC options are not underwritten. |
If you wish to exercise your options, you may do so in whole or in part.
Your enclosed option exercise form includes both your personalised BPAY and Electronic Funds Transfer (EFT) payment details.
The total exercise price for the options which you chose to exercise (if any) can be paid by BPAY or EFT, and the completed option exercise form (where applicable if opting NOT to exercise in full) can be returned to our Share Registry by email to [email protected].
For further instructions please see enclosed option exercise form.
If the options exercise form (where applicable if opting NOT to exercise in full), together with cleared funds, is not received by our share registry on or before the expiry date
==> picture [126 x 50] intentionally omitted <==
Imugene Limited Suite 12.01, Level 12 ABN 99 009 179 551 4-6 Bligh Street www.imugene.com Sydney NSW 2000 AUSTRALIA
(Wednesday, 30 November 2022), then your IMUOC options will expire with no value and no further entitlement will exist.
If you have any queries concerning this Notice or your option holding, please contact Automic on +61 (2) 8072 1400.
Sincerely,
Leslie Chong CEO & Managing Director Imugene Limited
All Registry Communication to:
==> picture [153 x 27] intentionally omitted <==
IMUGENE LIMITED | ACN 009 179 551
==> picture [243 x 90] intentionally omitted <==
GPO Box 5193, Sydney NSW 2001 1300 288 664 (within Australia) +61 2 9698 5414 (international) [email protected] www.automicgroup.com.au
SRN/HIN:
Security Code: IMUOC Number of Options held:
Option Expiry Date: 30 November 2022
Exercise Price: $0.054
Total Amount payable (exercising in full): $ NOTICE OF EXERCISE OF OPTIONS By making a BPAY® or EFT payment or returning this form together with confirmation of a BPAY or EFT payment, I/we hereby exercise the following number of options and make payment in Australian currency for the amount payable. Please allot me/us Ordinary Shares calculated on the basis of one Ordinary Share for every one Option which I/we exercise. I/We agree to accept such Shares subject to the Constitution of Imugene Limited. 1. Number of Options to be Exercised Total payment required @ $0.054 per Option , , A$ , , . If the dollar amount paid results in a fraction of a share then the shares allotted will be rounded down. 2. Payment: You can pay either by BPAY or EFT Option A – BPAY Option B – Electronic Funds Transfer (EFT) Biller Code: The unique payment reference number which has been assigned to your Application is: Ref No: Funds are to be deposited directly to following bank account: Account name: ® Registered to BPAY Pty Ltd ABN 69079137518 Account BSB: Account number: Contact your financial institution to make your payment from your Swift Code: cheque or savings account. IMPORTANT: You must quote your unique reference number as your Note: You do not need to return this form if you have made payment reference/ description when processing your EFT payment. Failure payment via BPAY®. Your BPAY® reference number will process to do so may result in your funds not being allocated to options exercise and your payment to your options exercise electronically. shares subsequently not issued. You should check the processing cut-off time for BPAY® transactions Note: You do not need to return this form if you have made payment via with your bank, credit union or building society to ensure your payment EFT. Your unique payment reference number will process your will be received by the Share Registry in time.
Note: You do not need to return this form if you have made payment via EFT. Your unique payment reference number will process your payment to your options exercise electronically.
3. Contact details & Elect to be an e-Shareholder
As a valued shareholder in Imugene Limited, you can help minimise the costs of printing and mailing by electing to receive all shareholder communications electronically. This will ensure you receive all future important shareholder communications in a faster and more secure way. Please enter your details and return to our Share Registry by email to [email protected].
Telephone Number ( )
Contact Name (PLEASE PRINT)
Email Address